Jupiter Topco LLC Acquires Shares of 21,058 Kymera Therapeutics, Inc. $KYMR

Jupiter Topco LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 21,058 shares of the company’s stock, valued at approximately $2,415,000.

Several other hedge funds have also recently bought and sold shares of KYMR. Smartleaf Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. GAMMA Investing LLC increased its stake in shares of Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics during the 4th quarter worth approximately $63,000.

Kymera Therapeutics Stock Down 0.4%

Shares of Kymera Therapeutics stock opened at $118.63 on Thursday. Kymera Therapeutics, Inc. has a 12-month low of $40.10 and a 12-month high of $130.05. The company has a market capitalization of $9.86 billion, a price-to-earnings ratio of -36.61 and a beta of 1.96. The firm’s 50-day moving average price is $113.96 and its two-hundred day moving average price is $94.49.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same period in the previous year, the company earned ($0.95) EPS. The business’s revenue for the quarter was up 465.2% compared to the same quarter last year. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer directly owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the sale, the director directly owned 472,267 shares in the company, valued at $52,086,327.43. This trade represents a 49.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,587,629 shares of company stock worth $386,183,782 over the last three months. 15.98% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on KYMR shares. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a research report on Monday, June 8th. BTIG Research reissued a “buy” rating and issued a $134.00 price objective on shares of Kymera Therapeutics in a report on Thursday, June 25th. Mizuho increased their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Bank of America raised their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, TD Cowen upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.70.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.